Synaptogenesis

Synaptogenesis is the biological process by which new synaptic connections form between neurons — the step at which a signaling junction is built where none existed before. Each synapse links a transmitting terminal on one cell to a receiving structure, most often a dendritic spine, on another.

The process runs at high speed during early brain development, when circuits are being assembled from scratch. It continues at lower rates throughout life, particularly in regions associated with learning and memory such as the hippocampus.

Synaptogenesis is distinct from neurogenesis, the birth of new neurons. Existing neurons form new synapses constantly without producing new cells; this is the more common form of adult plasticity, and the reason synaptogenesis is studied in its own right.

How it works · its role

Synapse formation begins when a growing axon terminal contacts a target dendrite. Proteins on each side — neurexins on the axon, neuroligins on the dendrite — act as molecular handshakes that anchor the junction and initiate assembly.

Once anchored, the presynaptic side builds the machinery for releasing neurotransmitter, while the postsynaptic side accumulates receptors and scaffolding needed to detect it. Dendritic spines emerge as small protrusions and enlarge as the connection matures.

Neural activity drives the whole process: junctions that fire together tend to be stabilized, while unused ones are pruned. BDNF (BDNF) is a key molecular signal at several points in this sequence, which is why it appears repeatedly in research on how substances alter synaptic structure.

Relevance to substances & effects

Several substance classes have drawn research interest for their apparent ability to promote synaptogenesis. Ketamine and related NMDA receptor antagonists rapidly increase dendritic spine density in prefrontal cortex in animal models — a finding thought to contribute to ketamine's fast-acting antidepressant properties.

Serotonergic psychedelics, including psilocybin, LSD, and DMT, have been shown in cell and animal studies to encourage synaptogenesis and dendritic spine growth, a property sometimes called psychoplastogenicity. Whether these structural changes translate meaningfully to human brains, and over what timescale, remains an open question.

Conventional antidepressants — SSRIs and SNRIs — raise BDNF levels over weeks of use, which is thought to support slower synaptogenic changes. Chronic heavy alcohol use appears to reduce synaptic density in certain brain regions; structural recovery during abstinence may partly involve renewed synaptogenesis, though the picture is not fully worked out.

Most direct evidence in this area comes from rodent models and cultured neurons. Human neuroimaging cannot resolve individual synapses, so claims about substance-driven synaptogenesis in people are better read as promising hypotheses than as established facts.